Skip to main content
SpringerLink
Log in

Evaluating the Use of Dexmedetomidine in Neurocritical Care Patients

  • Original Article
  • Published:
Neurocritical Care Aims and scope Submit manuscript

Abstract

Introduction

Dexmedetomidine is a highly selective α2-adrenoreceptor agonist that produces dose-dependent sedation, anxiolysis, and analgesia without respiratory depression. Dexmedetomidine has been used in critically ill medical, surgical, and pediatric patients, as an adjunct to sedation and/or for treating drug or alcohol withdrawal. Information regarding the dosing and utilization of dexmedetomidine has been derived primarily from studies in critically ill patients in the medical intensive care unit. There has been no study designed specifically to evaluate dexmedetomidine for these therapeutic uses in the neurocritical care population. The primary and secondary objectives were to evaluate the starting dose of dexmedetomidine for neurocritical care patients and to assess the effect on hemodynamic parameters, respectively.

Methods

This was a prospective, observational study conducted from October 2007 to March 2008. Patients were included if they were admitted to the Neuro-Intensive Care Unit and received dexmedetomidine infusion.

Results

Six patients met the criteria for the study. The mean initial dexmedetomidine infusion rate and mean maximum infusion rate were 0.67 ± 0.2 and 1.3 ± 0.5 mcg/kg/h, respectively. The mean duration of dexmedetomidine infusion was 66 ± 10 h. Two patients (33%) experienced a significant change in mean heart rate and systolic blood pressure after starting dexmedetomidine infusion.

Conclusion

Neurocritically ill patients may require high doses of dexmedetomidine to achieve desired levels of sedation. The high rates and long duration of dexmedetomidine infusion had a statistically, but not clinically, significant impact on hemodynamic parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Bekker A, Sturaitis MK. Dexmedetomidine for neurological surgery. Neurosurgery. 2005;57(Suppl 1):1–10. doi:10.1227/01.NEU.0000163476.42034.A1.

    Article  PubMed  Google Scholar 

  2. Prielipp RC, Wall MH, Tobin JR, Groban L, Cannon MA, Fahey FH, et al. Dexmedetomidine-induced sedation in volunteers decreases regional and global cerebral blood flow. Anesth Analg. 2002;95:1052–9. doi:10.1097/00000539-200210000-00048.

    Article  CAS  PubMed  Google Scholar 

  3. Gerlach AT, Dasta JF. Dexmedetomidine: an updated review. Ann Pharmacother. 2007;41:245–54. doi:10.1345/aph.1H314.

    Article  CAS  PubMed  Google Scholar 

  4. Product Information. Precedex (dexmedetomidine). Lake Forest, IL: Hospira; April 2004.

    Google Scholar 

  5. Shehabi Y, Ruettimann U, Adamson H, Innes R, Ickeringill M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med. 2004;30:2188–96. doi:10.1007/s00134-004-2417-z.

    Article  PubMed  Google Scholar 

  6. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30(1):119–41. doi:10.1097/00003246-200201000-00020.

    Article  PubMed  Google Scholar 

  7. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O’Neal PV, Keane KA, et al. The Richmond agitation-sedation scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002;166:1338–44. doi:10.1164/rccm.2107138.

    Article  PubMed  Google Scholar 

  8. Venn RM, Newman PJ, Grounds RM. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med. 2003;29:201–7.

    CAS  PubMed  Google Scholar 

  9. MacLaren R, Forrest LK, Kiser TH. Adjunctive dexmedetomidine therapy in the intensive care unit: a retrospective assessment of impact on sedative and analgesic requirements, levels of sedation and analgesia, and ventilatory and hemodynamic parameters. Pharmacotherapy. 2007;27(3):351–9. doi:10.1592/phco.27.3.351.

    Article  CAS  PubMed  Google Scholar 

  10. Kim E. Agitation, aggression, and disinhibition syndromes after traumatic brain injury. NeuroRehabilitation. 2002;17:297–310.

    PubMed  Google Scholar 

  11. Levy M, Berson A, Cook T, Bollegala N, Seto E, Turanski S, et al. Treatment of agitation following traumatic brain injury: a review of the literature. NeuroRehabilitation. 2005;20:279–306.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Virginia Health System, Charlottesville, VA, USA

    Tina M. Grof & Kathleen A. Bledsoe

Authors
  1. Tina M. Grof
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathleen A. Bledsoe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tina M. Grof.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grof, T.M., Bledsoe, K.A. Evaluating the Use of Dexmedetomidine in Neurocritical Care Patients. Neurocrit Care 12, 356–361 (2010). https://doi.org/10.1007/s12028-008-9156-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-008-9156-x

Keywords

Search

Navigation